Innate Pharma (IPHA) Competitors

$1.42 -0.01 (-0.35%)

Closing price 03:59 PM Eastern

Extended Trading

$1.42 0.00 (0.00%)

As of 04:04 PM Eastern

IPHA vs. CYRX, FULC, ZURA, AQST, and UPB

Should you be buying Innate Pharma stock or one of its competitors? The main competitors of Innate Pharma include CryoPort (CYRX), Fulcrum Therapeutics (FULC), Zura Bio (ZURA), Aquestive Therapeutics (AQST), and Upstream Bio (UPB). These companies are all part of the "pharmaceutical products" industry.

How does Innate Pharma compare to CryoPort?

Innate Pharma (NASDAQ:IPHA) and CryoPort (NASDAQ:CYRX) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

: CryoPort has a net margin of 42.35% compared to Innate Pharma's net margin of 0.00%. Innate Pharma's return on equity of 0.00% beat CryoPort's return on equity.
Company Net Margins Return on Equity Return on Assets
Innate Pharma N/A N/A N/A
CryoPort 42.35% -8.22% -4.84%
: Innate Pharma currently has a consensus price target of $5.00, suggesting a potential upside of 250.88%. CryoPort has a consensus price target of $14.44, suggesting a potential upside of 18.47%. Given Innate Pharma's higher possible upside, equities analysts plainly believe Innate Pharma is more favorable than CryoPort.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Innate Pharma
1 Sell rating(s)
1 Hold rating(s)

1 Buy rating(s)

1 Strong Buy rating(s)
2.50
CryoPort
1 Sell rating(s)

0 Hold rating(s)

8 Buy rating(s)

0 Strong Buy rating(s)
2.78
: In the previous week, CryoPort had 16 more articles in the media than Innate Pharma. MarketBeat recorded 17 mentions for CryoPort and 1 mentions for Innate Pharma. Innate Pharma's average media sentiment score of 0.59 beat CryoPort's score of -0.23 indicating that Innate Pharma is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Innate Pharma
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
CryoPort
3 Very Positive mention(s)
3 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
: CryoPort has higher revenue and earnings than Innate Pharma.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Innate Pharma $2.79M 48.02 -$55.64M N/A N/A
CryoPort $176.18M 3.47 $78.30M $1.32 9.23
: 0.2% of Innate Pharma shares are held by institutional investors. Comparatively, 92.9% of CryoPort shares are held by institutional investors. 31.9% of Innate Pharma shares are held by insiders. Comparatively, 10.0% of CryoPort shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
: Innate Pharma has a beta of 0.22, indicating that its stock price is 78% less volatile than the S&P 500. Comparatively, CryoPort has a beta of 1.75, indicating that its stock price is 75% more volatile than the S&P 500.

Company	Net Margins	Return on Equity	Return on Assets
Innate Pharma	N/A	N/A	N/A
CryoPort	42.35%	-8.22%	-4.84%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innate Pharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
CryoPort	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Innate Pharma	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CryoPort	3 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innate Pharma	$2.79M	48.02	-$55.64M	N/A	N/A
CryoPort	$176.18M	3.47	$78.30M	$1.32	9.23

Summary

CryoPort beats Innate Pharma on 8 of the 15 factors compared between the two stocks.

How does Innate Pharma compare to Fulcrum Therapeutics?

Innate Pharma (NASDAQ:IPHA) and Fulcrum Therapeutics (NASDAQ:FULC) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

: 0.2% of Innate Pharma shares are held by institutional investors. Comparatively, 89.8% of Fulcrum Therapeutics shares are held by institutional investors. 31.9% of Innate Pharma shares are held by insiders. Comparatively, 7.0% of Fulcrum Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
: Innate Pharma's return on equity of 0.00% beat Fulcrum Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Innate Pharma N/A N/A N/A
Fulcrum Therapeutics N/A -27.80% -26.32%
: Innate Pharma currently has a consensus price target of $5.00, suggesting a potential upside of 250.88%. Fulcrum Therapeutics has a consensus price target of $19.00, suggesting a potential upside of 170.85%. Given Innate Pharma's higher possible upside, equities analysts plainly believe Innate Pharma is more favorable than Fulcrum Therapeutics.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Innate Pharma
1 Sell rating(s)
1 Hold rating(s)

1 Buy rating(s)

1 Strong Buy rating(s)
2.50
Fulcrum Therapeutics
2 Sell rating(s)

1 Hold rating(s)

7 Buy rating(s)

0 Strong Buy rating(s)
2.50
: In the previous week, Fulcrum Therapeutics had 12 more articles in the media than Innate Pharma. MarketBeat recorded 13 mentions for Fulcrum Therapeutics and 1 mentions for Innate Pharma. Innate Pharma's average media sentiment score of 0.59 beat Fulcrum Therapeutics' score of 0.54 indicating that Innate Pharma is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Innate Pharma
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Fulcrum Therapeutics
3 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: Innate Pharma has a beta of 0.22, indicating that its stock price is 78% less volatile than the S&P 500. Comparatively, Fulcrum Therapeutics has a beta of 3.02, indicating that its stock price is 202% more volatile than the S&P 500.
: Innate Pharma has higher revenue and earnings than Fulcrum Therapeutics.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Innate Pharma $2.79M 48.02 -$55.64M N/A N/A
Fulcrum Therapeutics N/A N/A -$74.88M -$1.15 N/A

Company	Net Margins	Return on Equity	Return on Assets
Innate Pharma	N/A	N/A	N/A
Fulcrum Therapeutics	N/A	-27.80%	-26.32%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innate Pharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Fulcrum Therapeutics	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Innate Pharma	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Fulcrum Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innate Pharma	$2.79M	48.02	-$55.64M	N/A	N/A
Fulcrum Therapeutics	N/A	N/A	-$74.88M	-$1.15	N/A

Summary

Innate Pharma beats Fulcrum Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Innate Pharma compare to Zura Bio?

Innate Pharma (NASDAQ:IPHA) and Zura Bio (NASDAQ:ZURA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, institutional ownership, profitability, dividends and analyst recommendations.

: 0.2% of Innate Pharma shares are held by institutional investors. Comparatively, 61.1% of Zura Bio shares are held by institutional investors. 31.9% of Innate Pharma shares are held by company insiders. Comparatively, 14.2% of Zura Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
: Innate Pharma's return on equity of 0.00% beat Zura Bio's return on equity.
Company Net Margins Return on Equity Return on Assets
Innate Pharma N/A N/A N/A
Zura Bio N/A -59.06% -48.04%
: Innate Pharma presently has a consensus price target of $5.00, suggesting a potential upside of 250.88%. Zura Bio has a consensus price target of $10.75, suggesting a potential upside of 107.73%. Given Innate Pharma's higher probable upside, research analysts plainly believe Innate Pharma is more favorable than Zura Bio.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Innate Pharma
1 Sell rating(s)
1 Hold rating(s)

1 Buy rating(s)

1 Strong Buy rating(s)
2.50
Zura Bio
1 Sell rating(s)

1 Hold rating(s)

3 Buy rating(s)

1 Strong Buy rating(s)
2.67
: In the previous week, Zura Bio had 1 more articles in the media than Innate Pharma. MarketBeat recorded 2 mentions for Zura Bio and 1 mentions for Innate Pharma. Innate Pharma's average media sentiment score of 0.59 beat Zura Bio's score of 0.00 indicating that Innate Pharma is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Innate Pharma
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Zura Bio
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: Innate Pharma has a beta of 0.22, indicating that its share price is 78% less volatile than the S&P 500. Comparatively, Zura Bio has a beta of 0.09, indicating that its share price is 91% less volatile than the S&P 500.
: Innate Pharma has higher revenue and earnings than Zura Bio.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Innate Pharma $2.79M 48.02 -$55.64M N/A N/A
Zura Bio N/A N/A -$99.35M -$1.06 N/A

Company	Net Margins	Return on Equity	Return on Assets
Innate Pharma	N/A	N/A	N/A
Zura Bio	N/A	-59.06%	-48.04%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innate Pharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Zura Bio	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Innate Pharma	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zura Bio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innate Pharma	$2.79M	48.02	-$55.64M	N/A	N/A
Zura Bio	N/A	N/A	-$99.35M	-$1.06	N/A

Summary

Innate Pharma beats Zura Bio on 8 of the 12 factors compared between the two stocks.

How does Innate Pharma compare to Aquestive Therapeutics?

Aquestive Therapeutics (NASDAQ:AQST) and Innate Pharma (NASDAQ:IPHA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, dividends, earnings and analyst recommendations.

: Innate Pharma has a net margin of 0.00% compared to Aquestive Therapeutics' net margin of -188.09%.
Company Net Margins Return on Equity Return on Assets
Aquestive Therapeutics -188.09% N/A -64.46%
Innate Pharma N/A N/A N/A
: Innate Pharma has lower revenue, but higher earnings than Aquestive Therapeutics.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Aquestive Therapeutics $44.55M 11.66 -$83.78M -$0.78 N/A
Innate Pharma $2.79M 48.02 -$55.64M N/A N/A
: 32.5% of Aquestive Therapeutics shares are owned by institutional investors. Comparatively, 0.2% of Innate Pharma shares are owned by institutional investors. 8.4% of Aquestive Therapeutics shares are owned by insiders. Comparatively, 31.9% of Innate Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
: In the previous week, Aquestive Therapeutics had 14 more articles in the media than Innate Pharma. MarketBeat recorded 15 mentions for Aquestive Therapeutics and 1 mentions for Innate Pharma. Innate Pharma's average media sentiment score of 0.59 beat Aquestive Therapeutics' score of 0.00 indicating that Innate Pharma is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Aquestive Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
14 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Innate Pharma
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: Aquestive Therapeutics presently has a consensus price target of $8.80, suggesting a potential upside of 110.53%. Innate Pharma has a consensus price target of $5.00, suggesting a potential upside of 250.88%. Given Innate Pharma's higher possible upside, analysts plainly believe Innate Pharma is more favorable than Aquestive Therapeutics.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aquestive Therapeutics
1 Sell rating(s)
0 Hold rating(s)

5 Buy rating(s)

2 Strong Buy rating(s)
3.00
Innate Pharma
1 Sell rating(s)

1 Hold rating(s)

1 Buy rating(s)

1 Strong Buy rating(s)
2.50
: Aquestive Therapeutics has a beta of 1.5, meaning that its share price is 50% more volatile than the S&P 500. Comparatively, Innate Pharma has a beta of 0.22, meaning that its share price is 78% less volatile than the S&P 500.

Company	Net Margins	Return on Equity	Return on Assets
Aquestive Therapeutics	-188.09%	N/A	-64.46%
Innate Pharma	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aquestive Therapeutics	$44.55M	11.66	-$83.78M	-$0.78	N/A
Innate Pharma	$2.79M	48.02	-$55.64M	N/A	N/A

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aquestive Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	14 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Innate Pharma	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aquestive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	3.00
Innate Pharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Summary

Aquestive Therapeutics and Innate Pharma tied by winning 7 of the 14 factors compared between the two stocks.

How does Innate Pharma compare to Upstream Bio?

Upstream Bio (NASDAQ:UPB) and Innate Pharma (NASDAQ:IPHA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, dividends, earnings and analyst recommendations.

: 0.2% of Innate Pharma shares are owned by institutional investors. 13.6% of Upstream Bio shares are owned by insiders. Comparatively, 31.9% of Innate Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
: Upstream Bio presently has a consensus price target of $39.00, suggesting a potential upside of 328.05%. Innate Pharma has a consensus price target of $5.00, suggesting a potential upside of 250.88%. Given Upstream Bio's stronger consensus rating and higher possible upside, equities analysts plainly believe Upstream Bio is more favorable than Innate Pharma.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Upstream Bio
1 Sell rating(s)
1 Hold rating(s)

2 Buy rating(s)

1 Strong Buy rating(s)
2.60
Innate Pharma
1 Sell rating(s)

1 Hold rating(s)

1 Buy rating(s)

1 Strong Buy rating(s)
2.50
: Innate Pharma has a net margin of 0.00% compared to Upstream Bio's net margin of -5,026.03%. Innate Pharma's return on equity of 0.00% beat Upstream Bio's return on equity.
Company Net Margins Return on Equity Return on Assets
Upstream Bio -5,026.03% -36.48% -35.38%
Innate Pharma N/A N/A N/A
: Innate Pharma has lower revenue, but higher earnings than Upstream Bio.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Upstream Bio $2.85M 173.97 -$143.44M -$2.67 N/A
Innate Pharma $2.79M 48.02 -$55.64M N/A N/A
: In the previous week, Upstream Bio had 1 more articles in the media than Innate Pharma. MarketBeat recorded 2 mentions for Upstream Bio and 1 mentions for Innate Pharma. Upstream Bio's average media sentiment score of 1.18 beat Innate Pharma's score of 0.59 indicating that Upstream Bio is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Upstream Bio
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Innate Pharma
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: Upstream Bio has a beta of 1.28, meaning that its share price is 28% more volatile than the S&P 500. Comparatively, Innate Pharma has a beta of 0.22, meaning that its share price is 78% less volatile than the S&P 500.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Upstream Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Innate Pharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Company	Net Margins	Return on Equity	Return on Assets
Upstream Bio	-5,026.03%	-36.48%	-35.38%
Innate Pharma	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Upstream Bio	$2.85M	173.97	-$143.44M	-$2.67	N/A
Innate Pharma	$2.79M	48.02	-$55.64M	N/A	N/A

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Upstream Bio	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Innate Pharma	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Upstream Bio beats Innate Pharma on 8 of the 14 factors compared between the two stocks.

Get Innate Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IPHA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IPHA vs. The Competition

Export

Metric	Innate Pharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$133.84M	$3.39B	$6.25B	$11.87B
Dividend Yield	N/A	2.20%	2.73%	5.21%
P/E Ratio	N/A	38.92	29.03	28.47
Price / Sales	48.02	154.75	476.10	60.92
Price / Cash	N/A	57.88	27.62	36.52
Price / Book	-5.48	7.03	9.67	6.67
Net Income	-$55.64M	$23.62M	$3.55B	$332.53M
7 Day Performance	1.79%	3.78%	1.75%	2.03%
1 Month Performance	4.01%	7.30%	5.66%	9.23%
1 Year Performance	-36.38%	67.15%	34.42%	39.62%

Innate Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IPHA Innate Pharma	3.4701 of 5 stars	$1.43 -0.3%	$5.00 +250.9%	N/A	$133.84M	$2.79M	N/A	220	Gap Up
CYRX CryoPort	3.5372 of 5 stars	$10.10 -2.7%	$13.31 +31.8%	N/A	$521.05M	$176.18M	7.65	1,186	Trending News Earnings Report Analyst Downgrade Gap Up
FULC Fulcrum Therapeutics	1.6761 of 5 stars	$7.44 -3.6%	$19.00 +155.4%	N/A	$514.15M	$80M	N/A	100	Analyst Upgrade
ZURA Zura Bio	2.394 of 5 stars	$5.30 -2.0%	$10.75 +102.8%	N/A	$513.30M	N/A	N/A	3	Upcoming Earnings
AQST Aquestive Therapeutics	2.5541 of 5 stars	$4.09 -0.2%	$8.80 +115.2%	N/A	$509.57M	$44.54M	N/A	160	Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IPHA) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Innate Pharma (IPHA) Competitors

IPHA vs. CYRX, FULC, ZURA, AQST, and UPB

How does Innate Pharma compare to CryoPort?

Summary

How does Innate Pharma compare to Fulcrum Therapeutics?

Summary

How does Innate Pharma compare to Zura Bio?

Summary

How does Innate Pharma compare to Aquestive Therapeutics?

Summary

How does Innate Pharma compare to Upstream Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IPHA vs. The Competition

Innate Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Innate Pharma (IPHA) Competitors

IPHA vs. CYRX, FULC, ZURA, AQST, and UPB

How does Innate Pharma compare to CryoPort?

Summary

How does Innate Pharma compare to Fulcrum Therapeutics?

Summary

How does Innate Pharma compare to Zura Bio?

Summary

How does Innate Pharma compare to Aquestive Therapeutics?

Summary

How does Innate Pharma compare to Upstream Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IPHA vs. The Competition

Innate Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools